KPF
ABVX

K2 Principal Fund’s Abivax ABVX Stock Holding History

K2 Principal Fund’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.98M Buy
53,741
+31,241
+139% +$3.7M 0.42% 76
2025
Q4 		$3.03M Buy
+22,500
New +$2.45M 0.24% 121

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

K2 Principal Fund's ABVX Position: Q1 2026 in Review

K2 Principal Fund increased its Abivax (ABVX) stake by 139% in Q1 2026, buying an estimated $3.7M and bringing the position to 53,741 shares worth $5.98M. The position accounts for 0.42% of the portfolio, ranked #76.

K2 Principal Fund first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • K2 Principal Fund held 53,741 shares of Abivax worth $5.98M as of Q1 2026.
  • K2 Principal Fund bought 31,241 Abivax shares in Q1 2026, an estimated $3.7M.
  • Abivax made up 0.42% of K2 Principal Fund's portfolio in Q1 2026, its #76 holding.
  • K2 Principal Fund first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on K2 Principal Fund's 13F filing for Q1 2026, filed 14 May 2026.